Kindstar Globalgene Technology (HKG:9960) expects to record a loss of between 55 million yuan and 65 million yuan for the year 2024, compared with a profit of 36.4 million yuan a year prior, a Wednesday filing with the Hong Kong bourse said.
The clinical testing company attributed the loss mainly to high credit-impaired losses, a loss from the fair value change on fund investments needing to be recognized, and an effect on its operating leverage and scale effect due to a slowdown in demand and market changes.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。